Axillary lymph node dissection (ALND) may not be needed for patients with limited residual nodal burden in all biologic subtypes. Omission of ALND could be safely considered for patients who achieve …
Walid Khaled, PhD, on Friday discussed work to draw a map of how the breast changes during tumorigenesis and progression.
China’s NMPA has granted priority review to the NDA for savolitinib plus osimertinib in pretreated EGFR-mutated advanced NSCLC with MET amplification.
The European Commission has approved a type II variation extended indication for lazertinib plus amivantamab in frontline EGFR-mutated NSCLC.
Join the world’s leading hematology experts at Highlights of ASH in North America, a two-day program offered in multiple locations that highlights the most influential…
Neil Iyengar, MD, Memorial Sloan Kettering Cancer Center, New York, NY, comments on the potential of incretin mimetics to reduce breast cancer risk, particularly in…
Data from a phase 1b/2 study show a 78.6% ORR in patients with metastatic triple-negative breast cancer treated with PM8002/BNT327 plus nab-paclitaxel.
Cardiovascular disease (CVD) and cancer are the two leading causes of death in the U.S. According to researchers from The University of Texas MD Anderson…
FDA approves nivolumab and hyaluronidase-nvhy for subcutaneous injection
